Gene therapy for cancer

Surgery Today

Volumn 30, Issue 11, 2000, Pages 967-973

  Gunji, Yoshio ^a   Ochiai, Takenori ^a   Shimada, H ^a   Matsubara, H ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Cancer; Esophagus; Gene therapy

Indexed keywords

CANCER VACCINE; COMPLEMENTARY RNA; DNA; DNA VACCINE; LIPOSOME; PROTEIN P53; RNA; TUMOR ANTIGEN; VIRUS VECTOR;

CLINICAL PROTOCOL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ESOPHAGUS CANCER; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; ONCOGENE; REVIEW; SUICIDE GENE; TUMOR SUPPRESSOR GENE;

EID: 0033638217     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005950070015     Document Type: Review

References (39)

1. Experimental and clinical studies of cytokine gene-modified tumor cells
2. Murine colon carcinoma cells engineered to produce human interleukin-2 induce tumor-specific anti-tumor response
3. Antitumor effect induced by the expression of granulocyte macrophage-colony stimulating factor gene in murine colon carcinoma cells
4. Antitumor effect of murine colon carcinoma cells retrovirally-transduced with interleukin-4 and granulocyte macrophage-colony stimulating factor genes
5. Inhibition of peritoneal dissemination of murine colon carcinoma cells by administration retrovirus harboring IL-2 gene
6. Inhibition of experimental lung metastasis of murine colon carcinoma cells depends on the amount of interleukin-2 secreted from the transduced cells
7. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
8. Antitumor and antimetastatic activity of interleukin-12 against murine tumors
9. Antitumor effects of interleukin-12 (IL-12): Applications for the immunotherapy and gene therapy of cancer
10. Generation of antigen-specific CD8+ CTLs from naive precursors
11. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirustransduced murine dendritic cells
12. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha
13. Induction of systemic and therapeutic antitumor immunity Using intratumoral injection of dendritic cells genetically modified to express interleukin 12
14. Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2microglobulin gene in patients with cancer
15. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model
16. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the 'bystander effect'
17. Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer
18. Antisense oligonucleotides as therapeutic agents
19. Chemoprotection of normal tissues by transfer of drug resistance genes
20. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
21. Cell-cycle control and its watchman
22. Cancer therapy meets p53
23. P53 tumor suppressor gene therapy for cancer
24. Cell death and cancer: Replacement of apoptotic genes and inactivation of death suppressor genes in therapy
25. Viral vectors for gene therapy
26. Development and application of adenoviral vectors for gene therapy of cancer
27. Gene therapy - Promises, problems and prospects
28. Cationic liposome-mediated transfection
29. Progress in cancer gene therapy
30. Antitumor response of genetically engineered IL-2 expression to human esophageal carcinoma cells in mature T cell-defective condition
31. Induction of antitumor effect on human esophageal carcinoma cells by the retroviral expression Of granulocyte macrophagecolony stimulating factor gene
32. Differential efficacy of suicide gene therapy by herpes simplex virus-thymidine kinase gene reflects the status of p53 gene in human esophageal cancer cells
33. Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells
34. Preclinical study of p53 adenoviral gene therapy for esophageal carcinoma. The 4th annual meeting 1998
35. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus
36. Frequent mutation of the p53 gene in human esophageal cancer
37. Curative non-surgical combined treatment of squamous cell carcinom of the oesophagus
38. Optimal two-stage designs for phase II clinical trials
39. Adenovirus-mediated p53 gene transfer in advanced nonsmall-cell lung cancer